Pfizer
NEWS
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
Life sciences professionals don’t have to look far for opportunity in Genetown.
The company, which now has 11 personnel, is a CRO focused on infectious disease research.
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Since the acquisition fell apart, Allergan has fallen on some hard times.
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
Sangamo and Pfizer will use the company’s ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD.
JOBS
IN THE PRESS